This week's biggest % winners & losers: May 4 - 8, 20 (wk 19)

This week's biggest % gainers/losers The following are this week's top percentage gainers and losers, categorized by sectors (over $300 mln market cap and 100K average daily volume).

This week's top % gainers

• Healthcare: MGNX (20.34 +204.49%), PTLA (17.9 +154.26%), TGTX (18.82 +67.14%), AKBA (11.98 +50.13%), FPRX (4.11 +41.72%), BCRX (4.7 +32.77%), ADAP (4.44 +32.54%)
• Materials: RYAM (1.97 +34.01%)
• Industrials: ENPH (57.28 +32.44%)
• Consumer Discretionary: CWH (14 +70.11%), CHGG (63.13 +49.03%), AXL (5.96 +42.24%), NEW (7.6 +36.2%), OSTK (16.13 +34.64%),
• Information Technology: TWLO (179.69 +66.41%), LPSN (33.1 +47.31%), LASR (21.27 +43.81%), EVBG (153.87 +41.42%),
• Consumer Staples: NGVC (15.51 +47.86%)

This week's top % losers

• Healthcare: INGN (40.15 -22.1%), ELAN (19.84 -17.47%), QTNT (7.41 -16.46%)
• Industrials: PBI (2.54 -26.16%), SAVE (10.56 -19.82%), BCO (41.06 -15.71%)
• Consumer Discretionary: TLRD (1.09 -30.13%), JCP (0.17 -29.43%), GME (4.98 -17.69%), DESP (5.61 -16.02%)
• Financials: OXLC (3.37 -31.22%), BHLB (11.83 -26.84%), MITT (2.16 -25%), PRA (15.95 -20.73%), LC (5.95 -18.04%), SQQQ (10.64 -15.69%)

Portola (PTLA) to be acquired by Alexion (ALXN) for $18 /sh

Alexion Pharmaceuticals announced Tuesday that it would spend $1.4 billion to acquire Portola Pharmaceuticals, which sells a medicine called Andexxa used to stop life-threatening bleeding in patients who have been given certain anticoagulants.

   

 

Portola Pharma (PTLA) reported earnings on Thur 9 Aug 2018 (b/o)

 

Portola Pharma misses by $0.10, misses on revs 

• Reports Q2 (Jun) loss of $1.61 per share, $0.10 worse than the Capital IQ Consensus of ($1.51); revenues rose 5.8% year/year to $4.01 mln vs the $6.35 mln Capital IQ Consensus.
  • This includes $1.7 million in collaboration and license revenue earned under Portola's collaboration and license agreements with Bristol-Myers Squibb Company, Pfizer, Bayer Pharma, Janssen Pharmaceuticals and Daiichi Sankyo, as well as $2.2 million from initial sales of Andexxa in the U.S. under the Company's Early Supply Program launched in May 2018, and $33,000 in product revenue from sales of Bevyxxa, which launched in the U.S. in January 2018.

This week's biggest % winners & losers : April 30 - May 4, 18 (wk 18)

The following are this week's top 20 percentage gainers and top 20 percentage losers, categorized by sectors (over $300 mln market cap and 100K average daily volume).

This week's top 20 % gainers

• Healthcare: THC (31.23 +28.68%), CYH (4.79 +26.05%), CHRS (15.28 +24.44%), PTLA (42.11 +23.16%)
• Consumer Discretionary: SHAK (56.4 +19.34%), MBUU (40.74 +19.07%)
• Information Technology: NANO (35.46 +42.24%), P (6.98 +27.61%), MTSI (21.51 +26.46%), FDC (19.15 +25.33%), NSIT (43.39 +23.2%), RTEC (31.48 +22.23%), GLUU (5.3 +21.72%)
• Financials: FNGN (44.53 +31.15%), GHL (23.98 +18.69%)
• Energy: CRC (31.45 +28.31%), PES (4.48 +27.86%)
• Telecommunication Services: FTR (11.23 +33.31%)

This week's top 20 % losers

• Healthcare: AMN (51.73 -22.1%), CAH (52.84 -19.72%), OSUR (14.52 -19.69%), AKRX (11.78 -18.98%)
• Materials: GLT (16.52 -22.22%)
• Industrials: LKSD (12.4 -30.25%), QUAD (18.46 -26.27%), RRD (6.55 -25.57%), FLR (45.81 -23.94%), ARNC (17.24 -23.2%), PBI (8.65 -20.25%), JBT (88 -19.45%)
• Information Technology: COMM (27.97 -28.04%), DBD (11.78 -27.09%), MTCH (34.95 -24.04%)
• Energy: TCP (25.47 -25.83%), BAS (12.93 -19.44%)
• Telecommunication Services: S (5.28 -18.85%)

=Portola Pharma (PTLA) receives FDA approval for Andexxa

Portola Pharma receives FDA approval for Andexxa  

• Co announced that the FDA has approved Andexxa, the first and only antidote indicated for patients treated with rivaroxaban and apixaban, when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.
• Andexxa received both U.S. Orphan Drug and FDA Breakthrough Therapy designations and was approved under the FDA's Accelerated Approval pathway based on the change from baseline in anti-Factor Xa activity in healthy volunteers. Continued approval for this indication may be contingent upon post-marketing study results to demonstrate an improvement in hemostasis in patients.